Categories: News

ArisGlobal Launches LifeSphere Publishing as Key Component of LifeSphere Regulatory Cloud Platform

MIAMI, March 7, 2019 /PRNewswire/ — ArisGlobal, a leading provider of life sciences software that automates core drug development functions for over 200 life sciences companies, today announced LifeSphere® Publishing, a complete, pre-validated submissions management system that enables life science organizations to easily plan, compile, publish, and validate regulatory submissions with full support for all major global eCTD requirements. LifeSphere Regulatory Publishing can be used as a standalone application or as an integral part of ArisGlobal’s LifeSphere® Regulatory end-to-end cloud platform for regulatory affairs.

As part of the LifeSphere cognitive platform, LifeSphere Publishing works seamlessly with LifeSphere® EasyDocs, also announced today, to provide a fully unified content and submission management solution. Built on open SOA architecture, the solution offers configurable APIs to enable easy integration with other document management systems such as Documentum, D2, SharePoint, and more.

“Many life sciences companies face an increasing volume of digital assets being created and managed across multiple repositories. This reality makes it extremely difficult to have true visibility into where approved content exists across the organization and potentially leads to compliance issues,” said Wim Cypers, Senior Vice President, Regulatory Affairs of ArisGlobal. “LifeSphere Publishing and LifeSphere EasyDocs, in combination with LifeSphere Regulatory, help users to manage, in a single unified platform, all content related challenges and ensures compliance for years to come.”

LifeSphere Publishing offers feature-rich capabilities that deliver powerful benefits:

  • Seamless integration with regulatory information management, document management, and dossier management systems gives companies comprehensive capabilities across the product regulatory lifecycle
  • An intuitive, easy-to-use and mobile-enabled user interface enhances the user’s experience for compiling, publishing and validating submissions
  • Built-in document management functionalities with lifecycle and workflow management proactively navigate users through assigned activities
  • eCTD submission lifecycle management and support for FDA application and submissions ensure compliance
  • Pre-validated deployment on the state-of-the-art Amazon Web Services (AWS) cloud eliminates internal infrastructure and need for costly upgrades

Learn more: LifeSphere Publishing

About ArisGlobal
ArisGlobal is a visionary technology company that’s transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant Software-as-a-Service (SaaS) architecture. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. Visit arisglobal.com, or follow ArisGlobal on LinkedIn and Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/arisglobal-launches-lifesphere-publishing-as-key-component-of-lifesphere-regulatory-cloud-platform-300807991.html

SOURCE ArisGlobal

user

Recent Posts

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

8 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

8 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

8 hours ago